Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenetic Biosciences (XBIO) EBT Margin (2023 - 2025)

Xenetic Biosciences' EBT Margin history spans 7 years, with the latest figure at 81.3% for Q4 2025.

  • For Q4 2025, EBT Margin rose 8810.0% year-over-year to 81.3%; the TTM value through Dec 2025 reached 95.23%, up 7292.0%, while the annual FY2025 figure was 95.23%, 7292.0% up from the prior year.
  • EBT Margin reached 81.3% in Q4 2025 per XBIO's latest filing, down from 53.04% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 53.04% in Q3 2025 to a low of 248.31% in Q1 2024.
  • Average EBT Margin over 3 years is 150.73%, with a median of 164.13% recorded in 2025.
  • The largest YoY upside for EBT Margin was 10630bps in 2024 against a maximum downside of -9725bps in 2024.
  • A 3-year view of EBT Margin shows it stood at 186.87% in 2023, then grew by 9bps to 169.41% in 2024, then soared by 52bps to 81.3% in 2025.
  • Per Business Quant, the three most recent readings for XBIO's EBT Margin are 81.3% (Q4 2025), 53.04% (Q3 2025), and 122.8% (Q2 2025).